The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios

References

• Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(SpecFeature):105–110.
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a Phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. doi:10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399. doi:10.1111/bjd.14164
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–517. doi:10.1111/jdv.14015
   PubMed Web of Science ®Google Scholar
• Armstrong A, Levi E. Real-world clinical experience with apremilast in a large US Retrospective Cohort Study of patients with moderate to severe plaque psoriasis. J Drugs Dermatol. 2017;16(12):1240–1245.
   Web of Science ®Google Scholar
• Ighani A, Georgakopoulos JR, Walsh S, Shear NH, Yeung J. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2018;78(3):623–626. doi:10.1016/j.jaad.2017.09.060
   PubMed Web of Science ®Google Scholar
• Mayba JN, Gooderham MJ. Real-world experience with apremilast in treating psoriasis. J Cutan Med Surg. 2017;21(2):145–151. doi:10.1177/1203475416676030
   Web of Science ®Google Scholar
• Carrascosa JM, Belinchón I, Rivera R, Ara M, Bustinduy M, Herranz P. The Use of apremilast in psoriasis: a Delphi Study. Estudio Delphi para el uso de apremilast en la psoriasis. Actas Dermosifiliogr. 2020;111(2):115–134. doi:10.1016/j.ad.2019.07.005
   PubMed Web of Science ®Google Scholar
• Shah BJ, Mistry D, Chaudhary N, Shah S. Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe psoriasis. Indian Dermatol Online J. 2020;11(1):51–57. Published 2020 Jan 13.
   Google Scholar
• Parasramani S, Thomas J, Budamakuntla L, Dhoot D, Barkate H. Real-world experience on the effectiveness and tolerability of apremilast in patients with plaque psoriasis in India. Indian J Drugs Dermatol. 2019;5:83–88.
   Google Scholar
• De A, Das S, Dhoot D, Sarda A. Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience. Indian J Dermatol. 2020;65(5):396–400. doi:10.4103/ijd.IJD_194_19
   Web of Science ®Google Scholar
• Armesto S, González Vela C, Sánchez J, et al. Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatol Ther. 2020;33(6):e14464. doi:10.1111/dth.14464
   Web of Science ®Google Scholar
• Lee EB, Amin M, Wu JJ. Drug survival of apremilast in patients treated for psoriasis in a real-world setting. J Am Acad Dermatol. 2018;79(4):760–761. doi:10.1016/j.jaad.2018.03.028
   PubMed Web of Science ®Google Scholar
• Santos-Juanes J, Velasco L, Munguía-Calzada P, Lozano A, Gómez-Díez S. Comment on “Drug survival of apremilast for psoriasis in a real-world setting”. J Am Acad Dermatol. 2018;79(4):e83–e84. doi:10.1016/j.jaad.2018.05.1254
   Web of Science ®Google Scholar
• Del Alcázar E, Suárez-Pérez JA, Armesto S, et al. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2020;34(12):2821–2829. doi:10.1111/jdv.16439
   Web of Science ®Google Scholar
• AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a Retrospective Study. J Cutan Med Surg. 2016;20(4):313–316. doi:10.1177/1203475416631328
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou S, Nissel J, Wu A, Lau H, Palmisano M. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin Pharmacol Drug Dev. 2014;3(6):456–465. doi:10.1002/cpdd.109
   PubMed Web of Science ®Google Scholar
• Parasramani SG, Pillai J. Biologics in psoriasis: Indian experience. Indian J Drugs Dermatol. 2019;5(1):1–5. doi:10.4103/ijdd.ijdd_33_19
   Google Scholar
• Janagond AB, Palit A. Biologicals in the treatment of psoriasis: the Indian perspective. BLDE Univ J Health Sci. 2017;2:9–13. doi:10.4103/bjhs.bjhs_11_17
   Google Scholar
• Danesh MJ, Beroukhim K, Nguyen C, Levin E, Koo J. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015;21(6):13030/qt5gf406zs. doi:10.5070/D3216027825
   Google Scholar
• Rothstein BE, McQuade B, Greb JE, Goldminz AM, Gottlieb AB. Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis. J Drugs Dermatol. 2016;15(5):648–649.
   PubMed Web of Science ®Google Scholar
• De A, Das S, Dhoot D, Sarda A. Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic. Indian J Dermatol. 2019;64(3):239–241. doi:10.4103/ijd.IJD_548_18
   Web of Science ®Google Scholar
• Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol. 2017;42(4):471–473. doi:10.1111/ced.13065
   Web of Science ®Google Scholar
• Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142. doi:10.1016/j.jaad.2015.09.001
   PubMed Web of Science ®Google Scholar
• Ständer S, Syring F, Ludwig RJ, Thaçi D. Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series. Front Med. 2020;7:543944. doi:10.3389/fmed.2020.543944
   PubMed Web of Science ®Google Scholar
• Reich K, Bomas S, Korge B, et al. First “real-world” insights on apremilast therapy for patients with plaque psoriasis from the LAPIS-PSO study: an interim analysis. Available from: https://www.aad.org/eposters/submissions/getFile.aspx?id=5137&type=sub. Accessed April 4, 2019.
   Google Scholar
• Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77(5):690–698. doi:10.1136/annrheumdis-2017-211568
   PubMed Web of Science ®Google Scholar
• NICE guidance. Apremilast for treating moderate to severe plaque psoriasis. Available from: https://www.nice.org.uk/guidance/ta419/resources/apremilast-for-treating-moderate-to-severe-plaque-psoriasis-pdf-82604611623877. Accessed April 15, 2021.
   Google Scholar
• Verbenko DA, Karamova AE, Artamonova OG, et al. Apremilast pharmacogenomics in Russian patients with moderate-to-severe and severe psoriasis. J Pers Med. 2020;11(1):20. doi:10.3390/jpm11010020
   PubMed Web of Science ®Google Scholar
• Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75(12):1393–1403. doi:10.1007/s40265-015-0439-1
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients [published correction appears in J Am Acad Dermatol. 2020 Mar;82(3):574]. J Am Acad Dermatol. 2020;82(1):161–201. doi:10.1016/j.jaad.2019.08.049
   PubMed Web of Science ®Google Scholar
• Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389–397. doi:10.1016/j.jaad.2019.08.019
   PubMed Web of Science ®Google Scholar
• Smith RL. Pediatric psoriasis treated with apremilast. JAAD Case Rep. 2016;2(1):89–91. doi:10.1016/j.jdcr.2015.12.005
   PubMedGoogle Scholar
• Saporito RC, Cohen DJ. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 2016;8(2):179–184. doi:10.1159/000446836
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113.
   PubMed Web of Science ®Google Scholar
• Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017–2033. doi:10.1007/s12325-020-01346-6
   PubMed Web of Science ®Google Scholar
• Jindal S, Jindal N. Psoriasis and cardiovascular diseases: a literature review to determine the causal relationship. Cureus. 2018;10(2):e2195.
   Web of Science ®Google Scholar
• Mazzilli S, Lanna C, Chiaramonte C, et al. Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers. J Dermatol. 2020;47(6):578–582. doi:10.1111/1346-8138.15293
   PubMed Web of Science ®Google Scholar
• Duvetorp A, Mrowietz U, Nilsson M, Seifert O. Psoriasis is associated with a high comedication burden: a Population Based Register Study. Dermatol Ther. 2020;10(6):1285–1298. doi:10.1007/s13555-020-00442-3
   Web of Science ®Google Scholar
• Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897–903. doi:10.1080/14712598.2018.1504016
   PubMed Web of Science ®Google Scholar
• Otezla® (apremilast tablets) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2020.
   Google Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 Phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.e1. doi:10.1016/j.jaad.2017.01.052
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, De Lucia O. Efficacy and metabolic effect on serum lipids of apremilast in psoriatic arthritis: a case report. J Clin Med. 2019;8(3):398. doi:10.3390/jcm8030398
   Web of Science ®Google Scholar
• De La Rosa IA, López-Montilla M, Pérez-Sánchez C, et al. SAT0331 inflammatory markers and adipokines related to cardiovascular risk and metabolic comorbidities in psoriatic arthritis. in vivo effects of apremilast. Ann Rheum Dis. 2018;77(Suppl2):1030.2–1031.
   Google Scholar
• Liu H, Wilder T, Mediero A, Wei Z, Corciulo C, Cronstein B. Apremilast may improve atherosclerosis by promoting cholesterol efflux and inhibiting foam cell formation in atherosclerotic plaques [abstract]. Arthritis Rheumatol. 2016;68(suppl):10.
   Google Scholar
• Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–1551. doi:10.1038/jid.2013.508
   PubMed Web of Science ®Google Scholar
• Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798–807. doi:10.1111/jdv.13891
   PubMed Web of Science ®Google Scholar
• Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. J Eur Acad Dermatol Venereol. 2020;34(8):1755–1763. doi:10.1111/jdv.16231
   Web of Science ®Google Scholar
• Nast A, Spuls PI, van der Kraaij G, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951–1963. doi:10.1111/jdv.14454
   PubMed Web of Science ®Google Scholar
• Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J. 2019;10(1):1–12.
   PubMedGoogle Scholar
• Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian psoriasis collaboration. Australas J Dermatol. 2018;59(2):86–100. doi:10.1111/ajd.12641
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi:10.1038/nutd.2012.26
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31–44. doi:10.1016/j.ad.2012.08.003
   PubMedGoogle Scholar
• Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W. Diet and psoriasis, part I: impact of weight loss interventions. J Am Acad Dermatol. 2014;71(1):133–140. doi:10.1016/j.jaad.2014.02.012
   PubMed Web of Science ®Google Scholar
• Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study [published correction appears in JAMA Dermatol. 2013;149(8):997]. JAMA Dermatol. 2013;149(7):795–801. doi:10.1001/jamadermatol.2013.722
   PubMed Web of Science ®Google Scholar
• Egeberg A, Sørensen JA, Gislason GH, Knop FK, Skov L. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018 Jul 1;153(7):692]. JAMA Surg. 2017;152(4):344–349. doi:10.1001/jamasurg.2016.4610
   Web of Science ®Google Scholar
• Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291–299. doi:10.1016/j.jaad.2009.03.047
   PubMed Web of Science ®Google Scholar
• Montazeri A, Kanitakis J, Bazex J. Psoriasis and HIV infection. Int J Dermatol. 1996;35(7):475–479. doi:10.1111/j.1365-4362.1996.tb01658.x
   Web of Science ®Google Scholar
• Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018;101(1):38–56.
   Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590. doi:10.1016/j.bcp.2012.01.001
   PubMed Web of Science ®Google Scholar
• Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report. Indian J Dermatol. 2019;64(3):242–244. doi:10.4103/ijd.IJD_633_18
   Web of Science ®Google Scholar
• Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481–e482. doi:10.1111/jdv.14301
   PubMed Web of Science ®Google Scholar
• Sacchelli L, Patrizi A, Ferrara F, Bardazzi F. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther. 2018;31(6):e12719. doi:10.1111/dth.12719
   Web of Science ®Google Scholar
• Manfreda V, Esposito M, Campione E, Bianchi L, Giunta A. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med. 2019;131(3):239–240. doi:10.1080/00325481.2019.1575613
   PubMed Web of Science ®Google Scholar
• Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol. 2019;20(6):829–845. doi:10.1007/s40257-019-00457-3
   Web of Science ®Google Scholar
• Fotiadou C, Trakatelli M, Papathemeli D, Lazaridou E. Safety of apremilast in the treatsment of a psoriasis patient with chronic hepatitis B. Proceedings of the 5th World Psoriasis & Psoriatic Arthritis Conference; June 27–30; 2018; Stockholm, Sweden.
   Google Scholar
• Jeon C, Nakamura M, Sekhon S, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep. 2017;3(6):495–497. doi:10.1016/j.jdcr.2017.07.007
   PubMedGoogle Scholar
• Svanström C, Lonne-Rahm SB, Nordlind K. Psoriasis and alcohol. Psoriasis. 2019;9:75–79. doi:10.2147/PTT.S164104
   Web of Science ®Google Scholar
• Blednov YA, Da Costa AJ, Tarbox T, Ponomareva O, Messing RO, Harris RA. Apremilast alters behavioral responses to ethanol in mice: i. reduced consumption and preference. Alcohol Clin Exp Res. 2018;42(5):926–938. doi:10.1111/acer.13616
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem. 2017;24(28):3054–3067. doi:10.2174/0929867324666170530093902
   PubMed Web of Science ®Google Scholar
• Bordignon V, Bultrini S, Prignano G, et al. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents. 2011;25(2):213–220.
   PubMed Web of Science ®Google Scholar
• Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M. Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol. 2012;2012:747204. doi:10.1155/2012/747204
   Google Scholar
• REDITREX (Methotrexate) injection [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals, Inc; 2019.
   Google Scholar
• Sandimmune® (Cyclosporine oral solution, USP) oral solution [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
   Google Scholar
• HUMIRA (Adalimumab) injection [prescribing information]. North Chicago: Abbott Laboratories; 2011.
   Google Scholar
• COSENTYX® (Secukinumab) injection [prescribing information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2018.
   Google Scholar
• Langley A, Beecker J. Management of common side effects of apremilast. J Cutan Med Surg. 2018;22(4):415–421. doi:10.1177/1203475417748886
   PubMed Web of Science ®Google Scholar
• Gooderham M, Papp K. Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Lett. 2015;20(5):1–6.
   Google Scholar
• Abhishek D, Aarti S, Dhiraj D, Hanmant B. Apremilast titration: real word Indian experience. Clin Dermatol Rev. 2021.
   Google Scholar
• PrOTEZLA® (apremilast) tablets [product monograph]. Available from: https://www.amgen.ca/products/~/media/FB841218E06B4508B0E7213BC578E641.ashx. Accessed April 15, 2021..
   Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073. doi:10.1136/annrheumdis-2015-207963
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734. doi:10.3899/jrheum.151376
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026. doi:10.1136/annrheumdis-2013-205056
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44(8):873–884. doi:10.1111/1346-8138.13829
   PubMed Web of Science ®Google Scholar